title: [Breaking paradigms. Intestinal microbiota transplantation: Preliminar report].
abstract: In the fourth century, during the Chinese Dong Jin dynasty, the doctor Ge Hong described good results after the oral administration of a suspension prepared from human faeces in patients with severe diarrhoea or food poisoning. Faecal microbiota transplantation has been used for five years in order to treat different diseases in addition to the severe diarrhoea caused by Clostridium difficile1. This paper aims to confirm that intestinal microbiota transplantation succeeds in reducing the negative impact of diseases such as severe diarrhoea, irritable bowel syndrome, anxiety, allergies, metabolic syndrome and others and that it is not only indicated for severe diarrhoea caused by C. difficile. This preliminary study included six patients who underwent faecal microbiota transplantation, aged 83, 76, 66, 37 and 36 years (four men and two women). An improvement in symptoms of 70% was observed. The methodology and criteria to be followed with donors are described and the results are listed in three tables. The methodology followed for the microbiota transplant is the same as that reported by other researchers for the treatment of C. difficile diarrhoea and other diseases. The discussion addresses the issues raised in other parts of the world in handling different pathologic entities, as well as genetic advances. The conclusions show encouraging results.
authors.affiliation: Consulta privada, Ciudad de México, México. Electronic address: alzati58@hotmail.com.
authors.forename: Álvaro
authors.initials: Á
authors.lastname: Zamudio-Tiburcio
authors.affiliation: Servicio de Endoscopia, Hospital de Oncología del Centro Médico Nacional, Instituto Mexicano del Seguro Social, Ciudad de México, México.
authors.forename: Héctor
authors.initials: H
authors.lastname: Bermúdez-Ruiz
authors.affiliation: Servicio de Laboratorio Clínico, Hospital Trinidad, Ciudad de México, México.
authors.forename: Hugo Ricardo
authors.initials: HR
authors.lastname: Lezama-Guzmán
authors.affiliation: Servicio de Anestesiología, Hospital Magdalena de las Salinas, Instituto Mexicano del Seguro Social, Ciudad de México, México.
authors.forename: María Del Pilar
authors.initials: MDP
authors.lastname: Guevara-Ortigoza
authors.affiliation: Servicio de Laboratorio Clínico, Hospital Trinidad, Ciudad de México, México.
authors.forename: Elena
authors.initials: E
authors.lastname: Islas-Solares
authors.affiliation: Servicio de Laboratorio Clínico, Hospital Trinidad, Ciudad de México, México.
authors.forename: Francisco Antonio
authors.initials: FA
authors.lastname: Sosa-López
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001007:Anxiety / Q000209:etiology / Q000628:therapy*; D002446:Celiac Disease / Q000150:complications; D003106:Colon / Q000382:microbiology; D015897:Comorbidity; D000075203:Contraindications, Drug; D003967:Diarrhea / Q000209:etiology / Q000523:psychology / Q000628:therapy*; D043963:Diverticulosis, Colonic / Q000150:complications; D004404:Dysentery, Amebic / Q000188:drug therapy / Q000628:therapy; D004941:Esophagitis / Q000150:complications; D000069467:Fecal Microbiota Transplantation; D005260:Female; D000069196:Gastrointestinal Microbiome; D006551:Hernia, Hiatal / Q000150:complications; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000150:complications; D007583:Jejunum / Q000382:microbiology; D008286:Malabsorption Syndromes / Q000150:complications; D008297:Male; D008795:Metronidazole; D010865:Pilot Projects; D011804:Quinolines / Q000627:therapeutic use
chemical_list: D011804:Quinolines; D008795:Metronidazole; C026546:quinfamide
keywords: Faecal microbiota transplantation; Intestinal micro-organisms; Microbioma; Microbiome; Microbiota; Microorganismos intestinales; Trasplante de microbiota fecal